Replies to post #8619 on BioRestorative Therapies Inc (BRTX)

[trader59]

The 8K from the company says:

The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by the holders of the Company’s securities in the Chapter 11 Case. Based on the values for the Company’s business contemplated by the Asset Purchase Agreement referred to herein, the Company expects that existing Company stockholders will receive no recovery at the end of the Chapter 11 Case, consistent with legal priorities.

What more does anybody need to know?

[cash4]

Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) – DFS Caller
By daniellenierenberg

https://www.stemcelltherapy.me/financial-contrast-biorestorative-therapies-otcmktsbrtx-and-livongo-health-otcmktslvgo-dfs-caller/

BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (NASDAQ:LVGO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

0.1% of Livongo Health shares are owned by institutional investors. 17.9% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommendations for BioRestorative Therapies and Livongo Health, as reported by MarketBeat.

Livongo Health has a consensus target price of $44.30, indicating a potential upside of 71.17%. Given Livongo Healths higher probable upside, analysts plainly believe Livongo Health is more favorable than BioRestorative Therapies.

Profitability

This table compares BioRestorative Therapies and Livongo Healths net margins, return on equity and return on assets.

Valuation & Earnings

This table compares BioRestorative Therapies and Livongo Healths top-line revenue, earnings per share (EPS) and valuation.

BioRestorative Therapies has higher earnings, but lower revenue than Livongo Health.

Summary

Livongo Health beats BioRestorative Therapies on 7 of the 9 factors compared between the two stocks.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.

Livongo Health Company Profile

Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. The company was formerly known as EosHealth, Inc. and changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008 and is headquartered in Mountain View, California.

More:
Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller

[cash4]

Regarding the patent issued in Australia of BRT-100 is worth as much as the industry of disc and spine related issues, everyone has some back problems, workers in any field from construction, to wearhouse work, postal workers, enforcement officers, athletes...you name it, that alone could be millions.

https://www.globenewswire.com/news-release/2019/10/23/1934189/0/en/BioRestorative-Therapies-Receives-A-Second-Patent-in-Australia-For-Its-Metabolic-Program.html

MELVILLE, N.Y., Oct. 23, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Australia Patent Office has issued a Certificate of Grant for the Company’s patent application titled “Human Brown Adipose Derived Stem Cells and Uses.”

This is the second patent issued for the Company’s brown fat technology in Australia and adds to three other patents related to BioRestorative’s metabolic program (ThermoStem® Program) that have previously been issued to the Company in the United States and other countries.

Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

[cash4]

Patents Assigned to BIORESTORATIVE THERAPIES, INC.

https://patents.justia.com/assignee/biorestorative-therapies-inc

Brown fat cell compositions and methods
Patent number: 10597638
Abstract: Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes.
Type: Grant
Filed: July 1, 2013
Date of Patent: March 24, 2020
Assignee: BIORESTORATIVE THERAPIES, INC.
Inventors: Francisco Javier Silva, Mark Weinreb, Amit N. Patel, David A. Bull

Human brown adipose derived stem cells and uses
Patent number: 10167449
Abstract: An isolated human brown adipose tissue stem cell line. In one embodiment, the isolated human brown adipose tissue stem cell line expresses the markers CD9, SSEA4, CD44, CD90, CD166, CD73, but not CD14, CD34, CD45 or STRO-1. In another embodiment, the isolated human brown adipose tissue stem cell line expresses the genes UCP1, PPARGC1A, NRF1, FOXC2, CREB1, SIRT3, and WNT5A (REFX). In still another embodiment, the isolated human brown adipose tissue stem cell line is capable of differentiating into osteoblasts, chondrocytes, and adipocytes.
Type: Grant
Filed: April 17, 2014
Date of Patent: January 1, 2019
Assignee: BIORESTORATIVE THERAPIES, INC.
Inventor: Francisco Javier Silva

Brown fat cell compositions and methods
Patent number: 9133438
Abstract: Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes.
Type: Grant
Filed: June 28, 2012
Date of Patent: September 15, 2015
Assignee: BIORESTORATIVE THERAPIES, INC.
Inventors: Francisco Silva, Mark Weinreb, Amit N. Patel, David A. Bull

Human Metabolically Active Brown Adipose Derived Stem Cells
Publication number: 20140212875
Abstract: A method of distinguishing a brown adipose cell from a white adipose cell. In one embodiment the method includes measuring the expression level of one or more genes in an adipose cell; comparing the measured expression levels to a control, and correlating the expression level of the one or more genes to an identity as a white adipose cell or a brown adipose cell. In one embodiment the one or more genes are selected from the genes listed in FIG. 4C. In another aspect the invention relates to a method of differentiating an adipose stem cell. In one embodiment the method includes inducing differentiation of an adipose stem cell in vitro; and distinguishing the differentiated stem cell. In another embodiment the inducing is performed by contacting the adipose stem cell with a brown adipose cell differentiation media.
Type: Application
Filed: January 24, 2014
Publication date: July 31, 2014
Applicant: BioRestorative Therapies, Inc.
Inventor: Francisco Javier Silva

Brown Fat Cell Compositions and Methods
Publication number: 20130071360
Abstract: Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes.
Type: Application
Filed: June 28, 2012
Publication date: March 21, 2013
Applicant: BIORESTORATIVE THERAPIES, INC.
Inventors: Francisco Silva, Mark Weinreb, Amit N. Patel, David A. Bull